ArticleAbdominal radiology (New York)2026
Location- and ADC-based stratification of transition zone PI-RADS 3 lesions to optimize biopsy indication.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine whether anatomical location and apparent diffusion coefficient (ADC) risk stratification optimizes biopsy selection for PI-RADS 3 lesions in the transition zone (TZ).
methodsThis retrospective single-center study included 218 TZ PI-RADS 3 lesions in 128 patients who underwent radical prostatectomy between January 2014 and September 2023. Two radiologists identified 218 TZ PI-RADS 3 lesions in 128 patients on MRI and measured mean ADC; a third radiologist correlated imaging findings with whole-mount histopathology. Lesions located in the anterior apex, anterior mid-gland, or middle apex were classified as Location-risk positive; lesions with mean ADC < 0.800 × 10⁻³ mm²/s were classified as ADC-risk positive. Four virtual biopsy strategies were compared (conventional, Location-based, ADC-based, and Location + ADC-based). Outcomes included cancer detection rate (CDR), biopsy burden (performed/avoided), clinically significant prostate cancer (csPCa) yield (detected/missed), positive predictive value (PPV), and net benefit on decision curve analysis (thresholds, 5-25%).
resultsMean age was 68 ± 5.9 years (median, 69; range, 50-78). Among 218 lesions, 34 (16%) were csPCa. CDR was higher in location-risk positive than negative lesions (43% [28/65] vs. 4% [6/153]; p < 0.001) and in ADC-risk positive than ADC-risk negative lesions (47% [15/32] vs. 10% [19/186]; p < 0.001). Compared with conventional biopsy, the Location + ADC-based strategy reduced biopsies by 62% while detecting 31 of 34 csPCa lesions (91%) and missing 3 of 34 csPCa lesions (9%). Both location-informed strategies showed higher net benefit than the conventional across the evaluated thresholds.
conclusionFor TZ PI-RADS 3 lesions, combining anatomical location with an ADC threshold reduces unnecessary biopsies while preserving csPCa detection.
Indexed as
Identifiers
42387179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.